Clicky

Takeda Pharmaceutical Company Limited(TKPHF) News

Date Title
Jun 30 Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Jun 27 Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
Jun 27 Will Strong Asceniv Sales Drive ADMA Biologics Further?
Jun 25 Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
Jun 25 Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
Jun 25 ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
Jun 25 Takeda Announces New Assignments of Directors
Jun 24 Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
May 14 The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
Feb 15 Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
Feb 14 Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Feb 12 BBI announces $31m facility for Shire to enhance asset finance
Jan 2 Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.
Oct 9 WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
Jun 24 FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
Jun 24 Takeda reports positive data from Phase IIb trial of ITP treatment
Jun 24 EC approves Takeda’s Fruzaqla for metastatic colorectal cancer
Jun 24 Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
Jun 23 Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Jun 21 Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer